Literature DB >> 15488613

Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses.

Ludwig Deml1, Cornelia Speth, Manfred P Dierich, Hans Wolf, Ralf Wagner.   

Abstract

Several previous reports have clearly demonstrated the strong effectiveness of human immunodeficiency virus (HIV) Gag polyprotein-based virus-like particles (VLP) to stimulate humoral and cellular immune responses in complete absence of additional adjuvants. Yet, the mechanisms underlying the strong immunogenicity of these particulate antigens are still not very clear. However, current reports strongly indicate that these VLP act as "danger signals" to trigger the innate immune system and possess potent adjuvant activity to enhance the immunogenicity of per se only weakly immunogenic peptides and proteins. Here, we review the current understanding of how various particle-associated substances and other impurities may contribute to the observed immune-activating properties of these complex immunogens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15488613     DOI: 10.1016/j.molimm.2004.06.028

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  49 in total

1.  Dendritic cell-targeted lentiviral vector immunization uses pseudotransduction and DNA-mediated STING and cGAS activation.

Authors:  Jocelyn T Kim; Yarong Liu; Rajan P Kulkarni; Kevin K Lee; Bingbing Dai; Geoffrey Lovely; Yong Ouyang; Pin Wang; Lili Yang; David Baltimore
Journal:  Sci Immunol       Date:  2017-07-21

2.  Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state.

Authors:  Mikyung Kim; Zhisong Qiao; Jessica Yu; David Montefiori; Ellis L Reinherz
Journal:  Vaccine       Date:  2006-10-09       Impact factor: 3.641

Review 3.  Plant-derived virus-like particles as vaccines.

Authors:  Qiang Chen; Huafang Lai
Journal:  Hum Vaccin Immunother       Date:  2012-09-20       Impact factor: 3.452

Review 4.  Nanotechnology-based approaches for the development of diagnostics, therapeutics, and vaccines.

Authors:  Alagarsamy Srinivasan; Anshu Rastogi; Velpandi Ayyavoo; Shiv Srivastava
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-06

5.  Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity.

Authors:  Marc Kirchmeier; Anne-Catherine Fluckiger; Catalina Soare; Jasminka Bozic; Barthelemy Ontsouka; Tanvir Ahmed; Abebaw Diress; Lenore Pereira; Florian Schödel; Stanley Plotkin; Charlotte Dalba; David Klatzmann; David E Anderson
Journal:  Clin Vaccine Immunol       Date:  2013-12-11

6.  Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag.

Authors:  Kathlyn Santos; Cindy M P Duke; Sol M Rodriguez-Colon; Anthony Dakwar; Shongshan Fan; Michael C Keefer; Howard J Federoff; John G Frelinger; William J Bowers; Stephen Dewhurst
Journal:  Vaccine       Date:  2006-11-15       Impact factor: 3.641

7.  Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization.

Authors:  Jason Hammonds; Xuemin Chen; Timothy Fouts; Anthony DeVico; David Montefiori; Paul Spearman
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

8.  Use of the piggyBac transposon to create HIV-1 gag transgenic insect cell lines for continuous VLP production.

Authors:  Alisson G Lynch; Fiona Tanzer; Malcolm J Fraser; Enid G Shephard; Anna-Lise Williamson; Edward P Rybicki
Journal:  BMC Biotechnol       Date:  2010-03-31       Impact factor: 2.563

9.  Immunization with a Mixture of HIV Env DNA and VLP Vaccines Augments Induction of CD8 T Cell Responses.

Authors:  Ling Ye; Zhiyuan Wen; Ke Dong; Lei Pan; Zhigao Bu; Richard W Compans; Huizhong Zhang; Chinglai Yang
Journal:  J Biomed Biotechnol       Date:  2010-05-25

10.  HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice.

Authors:  Sirika Pillay; Enid G Shephard; Ann E Meyers; Anna-Lise Williamson; Edward P Rybicki
Journal:  J Immune Based Ther Vaccines       Date:  2010-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.